Latest

5-year CATT analysis finds anti-VEGF drugs a long-term AMD therapyAfter 5 years of follow-up in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), the visual acuity gains achieved during the first 2 years of anti-VEGF treatment were not maintained, the choroidal neovascular lesions continued to evolve with evidence of persistent activity in some eyes, and there was increased retinal thinning and geographic atrophy (GA).
Anti-PDGF inhibitor development continues despite negative resultsDespite the failure of 2 clinical trials involving a combination therapy of platelet-derived growth factor (PDGF) inhibitor and anti-vascular endothelial growth factor (anti-VEGF) therapy, a third phase III study continues.
Selective techniques revolutionize treatment for retinoblastomaAdvancements in retinoblastoma have occurred in the areas of treatment, genetic testing, and diagnostic imaging.
Targeted vitreoretinal lymphoma therapies mimic other approaches
Targeted vitreoretinal lymphoma therapies mimic other approachesVitreoretinal lymphomas are both deceptive and deadly. While there are only about 350 cases reported annually in the United States, median survival is less than 5 years, said Rajesh C. Rao, MD.
Tapping gene therapy potential for inherited retinal diseases
Tapping gene therapy potential for inherited retinal diseasesThe gene therapy technology already exists to treat most inherited retinal disease. The current challenge is to drive down the costs of implementing the technology.
FDA approves tocilizumab, first therapy for GCAThe FDA recently granted regulatory approval for tocilizumab (Actemra, Genentech), the first approved therapy for the treatment of adults with giant cell arteritis.
Pros and cons of compounded pharmaceuticalsCompounded pharmaceuticals have been used for decades, but does that mean they are reliable and safe? “Absolutely,” asserted Dante Pieramici, MD. “The literature disagrees,” said Julia Haller, MD.
New and different therapies emerging through uveitis pipelineLocal therapy plays a significant role in the treatment of uveitis, either as monotherapy or in combination therapy. Alongside a number of pharmacotherapeutic agents, new products and technologies are in development that could expand clinicians’ options and improve outcomes.
Endoillumination growth amplifies tissue visualizationEndoillumination for vitreoretinal surgery continues to improve with the introduction of brighter, safer light sources with color filters that may allow opportunities for better tissue visualization.
NICE recommends dexamethasone adalimumab for uveitisThe UK’s National Institute for Health and Care Excellence (NICE) has given preliminary approval to dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) and adalimumab (Humira, AbbVie) for sight-threatening non-infectious posterior uveitis.
var script= ' ';